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Apolipoprotein E (apoE) is a multifunctional glycosylated protein characterized by its wide tissue distribution. Despite its
importance in lipid transport and atherosclerosis pathogenesis, apoE is associated with neurodegenerative disorders such as
Alzheimer’sdisease(AD)andParkinsondisease,andautoimmunedisorderssuchasmultiplesclerosisandpsoriasis.Amongothers,
the role of apoE in modulating inﬂammation and oxidation is crucial in elucidating the risk factors of the above diseases since
the function of apoE is closely linked with both proinﬂammatory and antiinﬂammatory cytokines. Moreover, apoE modulates
inﬂammatory and immune responses in an isoform-dependent manner. Correspondingly, inﬂammatory cytokines can either
upregulate or downregulate the production of apoE in various tissue types. However, studies on the interactions between apoE
and cytokines occasionally yield conﬂicting results, highlighting the complex roles of apoE and cytokines in various disorders. The
present paper summarizes the current knowledge about the cross-talk between apoE and cytokines, with emphasis on the eﬀects
of apoE on the Th1/Th2 balance.
1.Introduction
Apolipoprotein E (apoE) was ﬁrst discovered in 1970s and
identiﬁed as a component of triglyceride-rich lipoprotein
complexes. Since then, apoE has been widely studied in lipid
metabolism, cardiovascular diseases [1], and neurodegen-
erative disorders such as Alzheimer’s disease (AD) [2]a n d
Parkinson disease (PD). In addition to its well-established
role in lipid transportation and atherosclerostic pathogen-
esis, apoE bears immunomodulatory properties and is asso-
ciated with multiple sclerosis (MS) [3] and psoriasis [4].
ApoE can modulate the functions of macrophages, suppress
the proliferation of T cells, maintain the integrity of blood-
brain barrier (BBB) and blood-nerve barrier (BNB), inhibit
theproliferationofsmoothmuscle(SM)cells,upregulatethe
production of nitric oxide (NO) of platelets, facilitate the
presentation of lipid antigen by CD1 molecules to natural
killer T (NKT) cells, and so forth, (Figure 1). Cytokines are
crucial in human inﬂammatory and autoimmune disorders
and apoE might aﬀect these disorders through interacting
with cytokines.
2. A GeneralView of Human ApoE, Its
Polymorphism, andItsReceptors
Human apoE is a 34.2kDa glycoprotein with 299 amino acid
residues. ApoE is produced by liver, brain, spleen, kidney,
lung and muscle tissues, and so forth. Hepatic parenchyma
cells produce 2/3 to 3/4 of the apoE in plasma [5]. In
the nervous system, apoE mRNA is present in astrocytes,
microglia, Schwann cells (SCs), neurons, and so forth,
(Figure 2)[ 6]. There are three major isoforms of human
apoE (apoE2, apoE3, apoE4) encoded by the ε2, ε3, and ε4
alleles on chromosome 19q13. Diﬀerences in the amino acid
residues (positions 112/158) of apoE distinguish the apoE2
(Cys/Cys), apoE3 (Cys/Arg), and apoE4 (Arg/Arg) isoforms.
The APOEε alleles show a peculiar distribution throughout
the world [7]; the APOEε3 allele is the most frequent in
populations with a long-established agricultural economy,
whereas the APOEε4 allele is the ancestral allele, with a
h i g h e rf r e q u e n c yi nP y g m i e s ,K h o iS a n ,P a p u a n s ,L a p p s ,a n d
some Native Americans [8]. The frequency of the APOEε4
allele also increases with latitude [9].2 Mediators of Inﬂammation
ApoE
functions on
Hepatocyte MΦ Tc e l l
SM cell
BBB and BNB
Platelet Others
Adipocyte
Maintain the integrity
↓ Proliferation ↑ NO production;
↑ VLDL production
↑ Lipoprotein clearance
↑ NO production;
↓ IL-12, TNF-α;
↓ MHCs expression
↓ Proliferation
Maintain the triglyceride
homeostasis
↑ Lipid antigen
presentation by CD1d
Figure 1: Schematic illustration of the biological properties of apoE. ApoE acts on adipocytes to maintain the triglyceride homeostasis;
acts on hepatocytes to promote very low density lipoprotein (VLDL) production and lipoprotein clearance; modulates the functions of
macrophages (MΦ); suppresses the proliferation of T cells; maintains the integrity of blood-brain barrier (BBB) and blood-nerve barrier
(BNB); inhibits the proliferation of smooth muscle (SM) cells; upregulates the production of nitric oxide (NO) of platelets; facilitates
the presentation of lipid antigen by CD1 molecules to natural killer T (NKT) cells; and so forth. ↑ denotes upregulation or induction; ↓
downregulation or inhibition; IL denotes interleukin; TNF-α denotes tumor necrosis factor alpha; MHC denotes major histocompatibility
complex.
The structural polymorphism in apoE inﬂuences its con-
formation and bindings to lipoprotein particles [10]a n dc e l -
lularreceptors[11].ApoE4preferentiallybindstolowerden-
sity lipoproteins and is associated with increased risk of ath-
erosclerosis and neurodegenerative disorders, including AD.
This binding preference is due to domain interaction (the
presenceofArg-112causesArg-61intheamino-terminaldo-
main to interact with Glu-255 in the carboxyl-terminal
domain) (Table 1). Additionally, physiological properties of
apoE, such as antioxidant [12], antiapoptotic [13], immun-
omodulatory [14], and atheroprotective capacities [15]a r e
signiﬁcantly inﬂuenced by apoE polymorphism.
ApoE exerts its biological functions, especially lipid
transportation, by binding to its receptors, the low-density
lipoprotein receptor (LDLR) family. The LDLR family
includes LDLR, LDLR-related protein 1 (LRP1), very low
density lipoprotein receptor (VLDLR), apoE receptor
(apoER)2, megalin (also known as LRP2) and LRP1B, and so
forth, [16]. As the prototype of this family, LDLR is the main
receptor for cholesterol metabolism [17], to which apoE3
and apoE4 bind with 50-fold greater aﬃnity than apoE2
[18].ApoEisessentialforthemetabolismoftriglyceride-rich
lipoprotein constituents. The interaction of apoE and LDLR
determines the removal of apoE-rich lipoproteins (VLDL,
chylomicron remnants, intermediate density lipoproteins),
and the homeostasis of cholesterol and triglycerides. Besides
direct signal transduction, the LDLR family functions as sig-
nal modulators and integrators in several signaling pathways
[19].
There is only one isoform of apoE in rodents. Murine
apoE preferably associates with HDL, and its clearance is
mainly through LDLR [20].
3. ApoE, Lipids, andInfections
The distribution of lipids among diﬀerent body compart-
ments occurs by means of diﬀerent lipoprotein particles
in the blood circulation [21]. Host responses to infections
involve changes in lipid levels and lipid metabolism in the
plasma. These plasma lipid changes might be mediated by
three cytokines interleukin (IL)-1, IL-6, and tumor necrosis
factor (TNF)-α, which induce elevated levels of triglycerides
and VLDL [22], decreased levels of cholesterol, HDL and
LDL [23, 24] or increased levels of cholesterol in the
serum [25], depending on the nature of the infectious
agents.
Lipoproteins and lipids present in the serum may con-
tribute to the host innate immunity against pathogens [26].
Studies using apoE deﬁcient mice conﬁrmed the role of
apoE in host susceptibility to endotoxemia and KlebsiellaMediators of Inﬂammation 3
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Figure 2: The synthesis and secretion of apoE. Hepatic parenchymal cells are the principal apoE producing cells, presumably accounting for
60% to 75% of apoE in plasma, followed by astrocytes, which are the main apoE producing cells in the nervous system. ApoE mRNA can
also be found in spleen, lung, kidney, peripheral nerves, muscular tissue, adrenal, ovary and testis, and so forth. In the nervous system, apoE
mRNA is present in astrocytes, nonmyelinating Schwann cells, ependymal cells, microglia, and neurons, and so forth. BCs denotes blood
cells; PNS denotes peripheral nervous system; CSF denotes cerebrospinal ﬂuid.
Table 1: The main diﬀerences among human apoE isoforms.
Isoform AA residues Domain interaction Binding to LDLR Lipoprotein-binding preference
112 158
ApoE 2 Cysteine Cysteine No Low aﬃnity HDL
ApoE 3 Cysteine Arginine No High aﬃnity HDL
ApoE 4 Arginine Arginine Yes High aﬃnity LDL
AA = amino acid.
LDLR = low density lipoprotein receptor.
pneumoniae infection [27], while transgenic (Tg) mice
expressing human APOEε3 and APOEε4g e n e sr e v e a l e d
an isoform-speciﬁc eﬀect of apoE on the proinﬂammatory
response to lipopolysaccharide (LPS) [28]. Infection of
apoE knockout (KO) mice with Listeria monocytogenes or
Klebsiella pneumoniae leads to an increased susceptibility
to death as well as increased serum levels of TNF-α as
compared with wild-type (WT) mice [29, 30]. Binding of
bacterial endotoxin to either HDL, LDL, or VLDL results
in a redirection of endotoxin uptake from Kupﬀer cells to
parenchymal hepatocytes where the endotoxin is deactivated
[30]. ApoE facilitated sepsis-induced mortality in a dose-
dependentmannerandincreasednaturalkillerT-(NKT)-cell
proliferation in the spleen [31]. ApoE deﬁcient mice were
markedly more susceptible to tuberculosis, evidenced by
100%mortalitywithin4weeksofinfectionwithtuberculosis
[32].
ApoE ε4/ε4 genotype was associated with an aggravated
disease course of acquired immunodeﬁciency syndrome
(AIDS), especially with accelerated progression to death.
Compared with apoE3, apoE4 enhanced human immunode-
ﬁciency virus (HIV) fusion/cell entry of both R5 and X4 HIV
strains in vitro [33] .A p o E 4c o m p e t e sl e s se ﬃciently than the
other isoforms for entry into neuronal cells through heparan
sulphate proteoglycan proteoglycans, which are involved in
HIV attachment and entry into cells [34]. HIV produces a
chronic viral infection in the central nervous system (CNS)
thatelicitschronicglialactivationandcytokinesoverproduc-
tion. Corder et al. showed that HIV-infected subjects with an
APOEε4 allele had excess peripheral neuropathy [35]. As a
well-known risk factor for AD [2], an ε4 allele along with the
presenceofherpessimplexvirus(HSV)1inthebrainconfers
an increased risk of developing to AD [36, 37].
The production of infectious hepatitis C virus (HCV)
was signiﬁcantly reduced by the knockdown of apoE. The
genotypes carrying the APOEε2 were associated with the
equivalent of a 3–5-fold reduction in the risk of chronic
HCVinfection[38].Anotherstudy,however,showedthatthe4 Mediators of Inﬂammation
expression of the apoE2 resulted in poorer recovery of infec-
tious HCV than did apoE3 and apoE4 isoforms [39]. Either
subjects without APOEε3 or with a single APOEε3w i t h
high serum cholesterol are prone to a better prognosis [40].
ApoE gene polymorphism was also associated with hepatitis
Bvirus(HBV)infection,andtheε2allele,comparedwiththe
other alleles, showed positive correlation with diﬀerent HBV
infection models [41].
4. Effects of ApoE on the Production of
Cytokinesandthe Maintenanceof the
THelper(Th)1/Th2 Balance
ApoE suppressed inﬂammation through VLDLR or apoER2
in macrophages by converting proinﬂammatory M1 to the
antiinﬂammatory M2 phenotype [42]. Exogenous apoE
suppressed LPS and polyinosine-polycytidylic acid (PIC, a
double-stranded RNA that serves as a viral mimetic and
a Toll-like receptor (TLR)3 agonist) induced secretion of
IL-6, IL-1β and TNF-α by RAW 264.7 cells via repressing
TLR-agonist-induced phosphorylation of c-Jun N-terminal
kinase (JNK) and c-Jun. ApoE peptide (141–155)2 inhibits
LPS- and PIC-induced macrophage inﬂammatory responses
in a similar manner [43]. ApoE also reduces inﬂammatory
signaling in astrocytes and microglia in response to proin-
ﬂammatory stimuli [44, 45].
Th precursor (THP) cells can diﬀerentiate into Th1, Th2,
or Th0 cells. Th0 cells can diﬀerentiate to Th1 and Th2
subpopulations depending primarily on the cytokines pro-
vided exogenously or from dendritic cells. Th1 cells are
involved in cellular immunity and immunoglobulin class
switching to the IgG2a isotype, whereas Th2 cells are mainly
associated with humoral immunity and immunoglobulin
class switching to IgG1 and IgE. Moreover, Th1 cells promote
the induction of complement-ﬁxing, opsonizing antibodies
and of antibodies involved in antibody-dependent cell cyto-
toxicity, for example, IgG2a in mice. Th1 cytokines include
interferon (IFN)-γ, IL-12, and TNF-α.T h e yc a na c t i v a t e
macrophages to produce reactive oxygen intermediates and
NO, stimulate their phagocytic functions, and enhance
their antigen presenting capacity by upregulating major
histocompatibility complex (MHC) class molecules. Th2
cytokines include IL-4, IL-5, IL-10, and IL-13, which provide
potent help for B-cell activation, immunoglobulin class
switching to IgE and IgG1 in the mouse, and downregulation
of macrophage activation (Figure 3).
Imbalance of the Th1/Th2 can result in autoimmune dis-
orders. In experimental autoimmune neuritis (EAN), an ani-
mal model of human Guillain-Barr´ e syndrome (GBS), Th1
cytokinespredominateandmediateinﬂammatorydamageto
the peripheral nerves, whereas Th2 cytokines are associated
with recovery from the disease [46–48]. Proinﬂammatory
cytokines such as IL-1β, IL-6, IL-12, IL-17, IL-18, IL-23,
TNF-α,I F N - γ, and macrophage inhibitory factor (MIF)
signiﬁcantly contribute to disease development of EAN by
recruiting eﬀector cells to the peripheral nervous system
(PNS) and by enabling in situ release of other products
toxic for SCs and myelin such as free radicals, oxygen
intermediates, and NO [46, 47, 49–51]. Antiinﬂammatory
cytokinesfromTh2cellssuchasIL-4andIL-10maysuppress
the disease by playing an important antiinﬂammatory role
[52, 53]. The balance of functionally distinct T-cell subsets
between Th1 and Th2 has a direct relevance to autoimmune
disorders.
Recently, the Th1/Th2 paradigm has been challenged,
following the discovery of a third subset of eﬀector Th
cells that produce IL-17 (termed Th17 cells) and exhibit
eﬀector functions distinct from Th1 and Th2 cells. Th17
cells are potent inducers of tissue inﬂammation and have
been associated with the pathogenesis of many autoimmune
diseases and rheumatic disorders [54]. IL17-producing Th17
cells have been found to play an important role in many
autoimmune diseases including experimental autoimmune
encephalomyelitis (EAE), an animal of MS, while thymic
regulatory T (Treg) cells have a suppressive role, although
their roles in EAN and GBS need further investigation [55].
Increased mRNA level of IL-1β, IL-2, IL-6, IFN-γ, intercel-
lular adhesion molecule (ICAM)-1, vascular cell adhesion
molecule (VCAM)-1, monocyte chemoattractant protein
(MCP)-1, nuclear factor (NF)κB (p65) and inhibitory (I)κB-
α and decreased mRNA level of IL-4, IL-10, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) in apoE
KO mice compared with WT mice imply that lacking
apoE promotes Th1 immune responses by changing these
cytokines [56]. IL-6, IL-12, TNF-α,a n dI F N - γ were upreg-
ulated to a signiﬁcantly greater level in apoE-deﬁcient mice
than in WT mice at both the mRNA and protein levels in
response to LPS administration. ApoE selectively regulates
TLR4- and TLR3-mediated signaling of IL-12 production
and apoE may suppress the Th1 immune response by
modulatingIL-12production[57].MacrophagesfromapoE-
deﬁcient mice stimulated by exogenous antigens are more
eﬀective in upregulating MHC class molecules and CD80,
with elevated secretion of IFN-γ in responding T cells
[58]. Severe hypercholesterolemia can induce a switch of
autoimmune responses from Th1 to Th2 eﬀector type in
atherosclerotic apoE KO mice [59]. ApoE-deﬁcient mice
injectedwithLPSproducedelevatedlevelsofIL-1β,IL-6,and
TNF-α, when compared with WT mice, and exogenous apoE
could reverse this eﬀect [60].
ApoE targets myeloid diﬀerentiation primary response
gene (MyD)88 and interleukin-1 receptor-associated kinase
(IRAK)1 activation whereby interrupting IL-1β and IL-18
signaling in vascular smooth muscle cells (VSMCs). As a
consequence, apoE can inhibit VSMC activation in response
to IL-18. IL-1β signaling intermediates NFκB transactivation
was inhibited by apoE in MyD88- and IRAK1- but not in
TRAF6-transfected cells. ApoE can prevent IRAK1 phospho-
rylation and IRAK1-TRAF6 but not MyD88-IRAK1 complex
formation [61].
NO is a principal eﬀector of macrophage-mediated
inﬂammatory/immune responses. In the mononuclear-
phagocyte system, NO is formed enzymatically from L-
arginine by inducible nitric oxide synthase (iNOS) [62].
Treatment of microglia and peripheral macrophages with
apoE increased NO production stimulated by IFN-γ and LPS
[63]. ApoE per se, however, seems unable alone to induce theMediators of Inﬂammation 5
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Figure 3: The T helper (Th)1/Th2 balance. Th1 cytokines, characterized by the production of interferon (IFN)-γ and interleukin (IL)-6, are
involved in cellular immunity and immunoglobulin class switching to the IgG2a isotype, whereas Th2 cytokines, characterized by IL-4 and
IL-10, are mainly associated with humoral immunity and immunoglobulin class switching to IgG1 and IgE. Th1 cells are the primary Th1
cytokine producing cells. Besides, natural killer (NK) cells and macrophage also contribute to the production of Th1 cytokines. Similarly,
Th2 cells produce the most Th2 cytokines in addition to mast cells and basophils. TNF-α denotes tumor necrosis factor alpha.
production of either iNOS; it functions via alteration of argi-
nine availability [64]. Furthermore, upon proinﬂammatory
stimulation, peripheral macrophages from male APOEε4
Tg mice could produce signiﬁcantly higher levels of NO
than from APOEε3T gm i c e[ 65]. Similar results were also
found in human studies [66]. The elevated NO production is
coupled with an increased arginine uptake in male APOEε4
Tg mice and is dependent on p38 mitogen-activited protein
kinase (MAPK) [67], whereas it is not the case in female
mice. Macrophages from female APOE Tg mice produce
higher levels of NO than male ones, without any isoform-
dependent diﬀerences [68].
SCs can secrete cytokines like IL-6 and IL-10 and actively
participate in immune responses as facultative antigen pre-
senting cells in the PNS [69]. The antigen presenting prop-
erties of SCs were enhanced in apoE KO mice, concomitant
with downregulated production of intracellular IL-6 [70].
In the recovery stage of EAN, NO produced by SCs is
pivotal for the termination of local immune responses by
inducing apoptosis of eﬀector T cells in the PNS [65]. ApoE
may regulate local inﬂammation in the PNS via modulating
cytokine andNOproduction. ApoE might actasaninhibitor
for EAN by suppressing the Th1 response and shifting the
Th1/Th2 to the Th2 direction. An increased susceptibility to
EAN after upregulation of the autoreactive T-cell response to
peripheral nerve component with higher levels of IFN-γ,I L -
12, and TNF-α and lower levels of IL-10was seenin apoE KO
mice than WT mice [71].
Signiﬁcantly increased secretion of Th17-related cytoki-
nes (IL-17 and IL-6) and expression of transcription factor
retinoid-related orphan receptor gamma (RORγ)t levels and
obviously decreased number in Treg cells, secretion of Treg-
related cytokines (TGF-β1) and expression of transcription
factor(Foxp3)levelswerefoundinapoEKOmice.Th17/Treg
functional imbalance exists in apoE KO mice, suggesting
a role of Th17/Treg imbalance in apoE functioning [72]. IL-
17A was also found to be elevated in the plasma and tissues
of apoE null mice [73].
COG133, a mimetic of apoE protein, when binding to
a protein transduction domain creates COG112, an anten-
napedia-linked apoE-mimetic peptide, improves therapeu-
tic eﬀects on EAE through decreasing demyelination and
diminishing the number of peripheral cells inﬁltrating into
the spinal cord, as well as other inﬂammatory processes
[74, 75]. Increased mRNA level of iNOS, TNF-α,I F N - γ,
and IL-17 and decreased nuclear translocation of NF-κB
and IκB kinase (IKK) activity in colitis models suggest that
COG112 inhibits inﬂammation through the NFκBp a t h w a y
[76]. Furthermore, intravenous administration of a small
apoE-mimetic peptide derived from the receptor-binding
region of the apoE holoprotein (apoE-(133–149)) similarly
suppressed both systemic and local brain inﬂammatory
responses in mice after LPS administration [28]. However,
diﬀerent genetic basis determines modiﬁed immunological
processes [77].
ApoE plays its nonlipid related roles by binding to cell
surface receptors [78]. LRP is implicated to mediate the
immunomodulatory eﬀects of apoE, although there seems to
be no diﬀerence in the binding aﬃnity of apoE isoforms to
LRP [79, 80].
5. Isoform-Dependent Effects of
ApoE on the Productionof Cytokines
ApoE suppressed the secretion of TNF-α and IL-1β in an
isoform-speciﬁc fashion (E2 > E3 > E4) [67]. A markedly
higher level of TNF-α was observed in supernatant of
cultured macrophage derived from adult male APOEε4T g
mice compared with macrophages from APOEε3o n e s[ 81].6 Mediators of Inﬂammation
In the presence of LPS, apoE3-expressing cells produce less
TNF-α and IL-6 than apoE2 and apoE4-expressing cells
whichmightberelatedwiththeextracellularsignal-regulated
kinases (ERK)1/2 signaling pathways [82]. ApoE genotype
pronouncedly aﬀects the cellular immune response in stably
transfected murine macrophages. In apoE4 versus apoE3
macrophage cell line cells higher levels of proinﬂammatory
cytokines including TNF-α appeared evident followed by
LPS stimulation [83]. Preincubation with human recombi-
nantapoEblockedglialsecretionofTNF-αinmixedneuron-
glial cultures in response to LPS stimulation in a dose-
dependent manner (apoE3 > apoE4). This eﬀect was the
greatest when apoE was preincubated for 24 hours and was
not dependent on any direct eﬀect of apoE on cell viability
[84].
Twice as many apoE4 carriers were demented (30%
versus 15%) or had peripheral neuropathy as compared with
non-apoE4 carriers in the HIV infection [35]. If there are
apoEisoform-dependentdiﬀerencesintheantiinﬂammatory
function of apoE in vivo,s u c hd i ﬀerences might in part
explain the diﬀerential risk for AD caused by apoE isoforms.
However, several studies demonstrated that exogenously
applied apoE4 had robust proinﬂammatory activity in astro-
cytes and microglial cells [85, 86]. In mice receiving the basal
diet without quercetin supplementation, levels of TNF-α in
whole blood stimulated ex vivo with LPS were higher in
apoE3 than apoE4 Tg mice [87].
ApoE displayed an isoform-speciﬁc eﬀect on inﬂamma-
tion in primary adult microglia culture, with apoE4 the
most potent to stimulate production of prostaglandin-E2
and IL-1β [88]. Activation of primary astrocytes from APOE
targeted replacement (TR) mice with LPS led to genotype-
dependent diﬀerences in cytokine secretion that were the
greatest in APOEε2 TR mice (APOE2 > APOE3 > APOE4)
[89]. Activation of primary astrocytes from APOE TR mice
with LPS led to APOE-dependent diﬀerences in cytokine
secretion that were greatest in APOEε2 TR mice and that
were associated with diﬀerences in NFκB subunit activity
[89].
Transforming growth factor (TGF)-β1 contains similar
structure with apoE and lipoproteins containing the apoE3
isoform have higher TGF-β levels and bioactivity than
those containing apoE4. Association of TGF-β with diﬀerent
types of lipoproteins may be beneﬁcial to diseases like
atherosclerosis and AD [90].
Intraventricular administration of LPS resulted in higher
productionofproinﬂammatorycytokines,alongwithgreater
activation of NFκB-regulated genes in the apoE4 than in
apoE3 Tg mice [91]. Inﬂammatory responses of APOEε4T R
micefollowingintravenousadministrationofLPSexpressing
the human APOEε4 allele had higher systemic and brain
levels of the proinﬂammatory cytokines TNF-α and IL-
6 than their apoE3 counterparts, suggesting an isoform-
speciﬁc eﬀect of the immunomodulatory properties of apoE
[28].
COG1410, an apoE-mimetic peptide, was also associated
with a reduction in TNF-α,I L - 1 β, IL-6, and IL-12 levels in
both apoE3 TR and apoE4 TR mice assessed at 24 hours in
the caecal ligation and puncture model of peritonitis [92].
Peripheral blood mononuclear cells (PBMCs) from AD
patients with APOEε4 allele produced higher spontaneous
and phorbol-12-myristate-13-acetate-(PMA-) induced levels
of IL-1β after controlling for confounders. APOE4ε carriers
showed higher concentrations of IL-1β than their coun-
terparts without APOEε4 after PMA-stimulation [93]. The
APOEε4 allele was associated with lower serum levels of
IL-10 in both acute coronary syndrome and chronic stable
anginapatients[94].RecombinantapoEsuppresseschemok-
ine (C–C motif) ligand (CCL)2 and vascular endothelial
growth factor (VEGF) expression in retinal pigment epithe-
lium (RPE) cells in an isoform-dependent manner (apoE4
> apoE3) [95]. The exact molecular mechanisms by which
apoE isoforms diﬀerentiallyalterthe immune responses have
been postulated to inﬂuence diﬀerent signaling pathways.
ApoE isoforms might be in part responsible for the diﬀeren-
tial modulation of NFκB and MAPK pathways [89, 91, 96].
A signiﬁcant interaction between APOE genotype and
the response to 17β-estradiol was observed for NO and
TNF-α production from microglia activated by recombinant
mouse IFN-γ plus either LPS or PIC. The antiinﬂammatory
activity of 17β-estradiol is pronouncedly reduced in APOEε4
TR mice compared with APOEε3 TR mice. ApoE genotype
may aﬀe c tt h en e u r o p r o t e c t i v er o l eo f1 7 β-estradiol and of
hormone replacement therapy on brain function when the
APOEε4 gene is expressed [96].
6. Effects of Cytokines on the Production
of ApoE in Various Tissues
Classical activation of macrophages by proinﬂammatory
cytokines such as IFN-γ and TNF-α can downregulate
apoE production [97–99]. However, antiinﬂammatory stim-
uli such as TGF-β and estrogen promote apoE synthesis
and release [100]. GM-CSF stimulated macrophages had a
3–5-fold reduction in apoE secretion, comparable with that
observed for IFN-γ, while TNF-α and IL-1β resulted in a 2-
fold decrease. In contrast to the reduction in apoE secretion
by these cytokines, TGF-β stimulated macrophages secreted
3-fold greater amounts of apoE than controls [100–103].
T r e a t m e n to fp r i m a r yr a ta s t r o c y t ea n dm i x e dg l i a lc e l l
cultures with TNF-α markedly reduced extracellular apoE
protein levels [104]. The eﬀects of apoE in adipose tissue on
body lipid homeostasis and atherosclerosis have been widely
studied [105]. ApoE is important in modulating triglyceride
metabolism in adipocytes. TNF-α can suppress the synthesis
of apoE in adipocytes [106]. TNF-α may activate the binding
of NFκB p50 to a binding site at -43 in the apoE promoter.
TreatmentofadipocyteswithTNF-αledtoincreasedbinding
of NFκB p50, decreased binding of p65 and Sp1 to this
region of the apoE promoter, and repression of adipocyte
apoE gene expression. Reduction of p50 expression using
siRNA completely eliminated TNF-α-mediated reduction of
endogenous apoE gene expression in adipocytes [107].
IFN-γ dramatically increased the degradation of intra-
cellular apoE and inhibited the accumulation of apoE in the
supernatants of human monocyte-derived macrophages and
human acute monocytic leukemia cell line (THP-1) cells via
post-translational modiﬁcation of apoE [97, 108]. IFN-β1bMediators of Inﬂammation 7
has inhibitory eﬀects on the production of apoE mRNA,
cellular protein, and secreted protein in blood monocytes
[109]. Treatment of primary mixed glial cell cultures with
IL-1β induced a marked increase of extracellular apoE pro-
tein. TGF-β can induce the expression of apoE in the THP-
1 cell line by activating JNK, MAPK p38 and caseine kinase
(CK)2pathways.Pharmacologicalinhibitorscanpreventthis
action [110].
7. Concluding Remarks
ApoE plays a pivotal role in maintaining the Th1/Th2 bal-
ance. Exogenous apoE suppressed the production of proin-
ﬂammatory cytokines in an isoform-speciﬁc manner. Classi-
cal activation of macrophages by proinﬂammatory cytokines
can downregulate apoE production and antiinﬂammatory
stimuli can promote apoE synthesis and release, indicating a
keyroleofapoEandcytokinesinimmunomodulation.ApoE
suppressing proinﬂammatory signalings, and vice versa,
indicate an intricate apoE-mediated feedback regulation of
inﬂammatory and immune responses.
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